Plenty of pharmaceuticals are put to market with the promise of improving people’s lives. Rarer still, are the medicines good enough to actually save lives. With plazomicin, the San Francisco-based Achaogen is chasing the latter. A next-generation antibacterial, designed to treat a host of serious drug-resistant infections (a huge issue in hospitals), the drug proved […]